Sonnet BioTherapeutics Holdings (SONN) said Wednesday it has received a patent from the US Patent and Trademark Office for its SON-1411 and SON-1400 immunotherapeutic drug candidates.
The patent, which covers a variant of recombinant human interleukin-18 contained in the two drug candidates, is effective until June 2044, Sonnet said.
SON-1411, a bifunctional fusion protein, and SON-1400, a monofunctional fusion protein, are linked to Sonnet's fully human albumin binding platform, the company said.
Shares of Sonnet rose more than 119% in early Wednesday trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。